Tyme Technologies To Present at BioNJ's 9th Annual BioPartnering Conference on May 8th, 2019

20:00 EDT 1 May 2019 | Globe Newswire

NEW YORK, May 02, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present a corporate overview for 2019 at the BioNJ 9th Annual BioPartnering Conference on Wednesday, May 8, 2019. Co-sponsored by J.P. Morgan and Johnson & Johnson Innovation, the conference brings together biopharmaceutical companies, investors, and academic collaborators across the Northeast to Mid-Atlantic states.

Event: BioNJ's 9th Annual BioPartnering Conference
Place: The Palace at Somerset Park in Somerset, NJ
Presentation Time: May 8th, 2019, 2:00 PM ET 

The presentation will be accessible on the events page under the Investor Relations section of Tyme Technologies’ website at There is no webcast for this event.

About Tyme Technologies
Tyme Technologies, Inc., is an emerging biotechnology company developing cancer metabolism-based therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system. For more information, visit Follow us on social media: @tyme_Inc, LinkedIn, Instagram, Facebook and YouTube.

Forward-Looking Statements/Disclosure Notice
In addition to historical information, this press release contains forward-looking statements under the Private Securities Litigation Reform Act that involve substantial risks and uncertainties. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of TYME's control. Factors that could cause actual results to differ materially from these forward-looking statements include the Company’s ability to successfully implement its clinical and other plans, competitive and regulatory developments, and the factors described in the section captioned “Risk Factors” of TYME’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”) on June 13, 2018, as well as subsequent reports and filings from time to time with the SEC.

The information contained in this press release is as of release date and TYME assumes no obligation to update forward-looking statements contained in this release as a result of future events or developments.


Ashley R. Robinson
LifeSci Advisors, LLC

Source: Tyme Technologies, Inc. 



More From BioPortfolio on "Tyme Technologies To Present at BioNJ's 9th Annual BioPartnering Conference on May 8th, 2019"

Quick Search


Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...